Company profile
Innoviva, Inc.
NASDAQ: INVA · Healthcare · Biotechnology
#227 of 1,418 Healthcare companies by revenue61st-percentile growth
EA Score
83B+FH 88DQ 87GM 65SS 77
v0.1 · 65/100 weight · provisional
↑ net margin, operating margin · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$424.1M
Rev growth YoY (TTM)
+13.6%
Net income (FY)
$271.2M
Employees
159
as of 2026-08-09
Market cap
$1.5B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$411.3M$411.3M2025
Net income$271.2M$271.2M2025
Operating income$163.7M$163.7M2025
Total assets$1.6B$1.6B2025
Equity$1.2B$1.2B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Royalty57%
Product42%
License And Other Revenue1%
By geography
Not disclosed.
The read
What is Innoviva, Inc.’s revenue?
Innoviva, Inc. booked $411.3M in FY2025 revenue, growing 15% year over year — faster than most Healthcare companies we track, at a 65.9% net margin.
Peers · Healthcare
GeneDx Holdings Corp.64CCertara, Inc.68BMiMedx Group, Inc.85AArdelyx, Inc.68BEsperion Therapeutics, Inc.61CKrystal Biotech, Inc.77B+Neighbors
San Mateo →Key facts
CEOPavel Raifeld
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlingame, CA
ExchangeNASDAQ: INVA
Employees159
IPO date2004-10-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.